Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$7.57
+1.0%
$8.06
$5.20
$10.67
$1.03B1.161.37 million shs1.01 million shs
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
$122.21
$123.21
$28.39
$132.54
$4.75B-0.16128,113 shsN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$79.98
-0.2%
$84.17
$64.94
$90.04
$3.95B0.43306,011 shs243,045 shs
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$76.01
$75.83
$23.77
$82.20
$3.81B-0.181.14 million shs4,322 shs
Xencor, Inc. stock logo
XNCR
Xencor
$8.41
+1.3%
$8.71
$7.16
$27.24
$599.26M0.85679,301 shs306,907 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%-12.43%-5.31%-3.12%+38.32%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.00%-1.26%-5.82%-3.46%+19.00%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00%0.00%0.00%0.00%0.00%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+3.26%-7.64%-3.28%-54.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.0945 of 5 stars
3.51.00.00.02.40.82.5
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.2296 of 5 stars
2.34.00.03.52.91.71.9
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
4.0286 of 5 stars
3.42.00.03.92.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5052.00% Upside
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.00
N/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$93.3316.70% Upside
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00
N/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00233.14% Upside

Current Analyst Ratings Breakdown

Latest PBH, TPTX, AUPH, EIDX, and XNCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
4/30/2025
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$31.00
4/21/2025
Xencor, Inc. stock logo
XNCR
Xencor
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.13$0.31 per share24.61$2.68 per share2.82
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
$26.69M177.99N/AN/A$4.57 per share26.74
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14B3.47$5.21 per share15.34$37.04 per share2.16
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$30.83M123.46N/AN/A$15.84 per share4.80
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M5.41N/AN/A$9.63 per share0.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2827.0213.51N/A16.11%14.27%9.93%7/30/2025 (Estimated)
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$214.60M$4.2918.6416.802.4018.86%12.87%6.78%8/6/2025 (Estimated)
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/A
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest PBH, TPTX, AUPH, EIDX, and XNCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/8/2025Q4 2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.30$1.32+$0.02$1.00$289.36 million$296.52 million
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.14
11.10
11.10
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.55
4.20
2.82
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/A
16.83
16.83
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
7038.87 millionN/ANot Optionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
54049.42 million48.62 millionOptionable
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
25050.07 million45.77 millionNot Optionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.78 millionOptionable

Recent News About These Companies

Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair
Xencor participates in a conference call with JPMorgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$7.57 +0.08 (+1.01%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$7.56 0.00 (-0.01%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Eidos Therapeutics stock logo

Eidos Therapeutics NASDAQ:EIDX

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$79.98 -0.20 (-0.25%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$79.82 -0.16 (-0.19%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Turning Point Therapeutics stock logo

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Xencor stock logo

Xencor NASDAQ:XNCR

$8.40 +0.11 (+1.27%)
Closing price 07/3/2025 01:23 PM Eastern
Extended Trading
$8.40 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.